Nectar Lifesciences is currently trading at Rs. 33.80, up by 1.95 points or 6.12% from its previous closing of Rs. 31.85 on the BSE.
The scrip opened at Rs. 34.50 and has touched a high and low of Rs. 34.70 and Rs. 33.25 respectively. So far 133153 shares were traded on the counter.
The BSE group 'B ' stock of face value Re. 1 has touched a 52 week high of Rs. 44.65 on 16-Sep-2014 and a 52 week low of Rs. 24.60 on 14-Aug-2014.
Last one week high and low of the scrip stood at Rs. 33.30 and Rs. 30.95 respectively. The current market cap of the company is Rs. 758.00 crore.
The promoters holding in the company stood at 44.35 % while Institutions and Non-Institutions held 14.57 % and 20.56 % respectively.
Nectar Lifesciences, the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has received ANVISA cGMP (Current Good Manufacturing Practices) approval for Brazil for its Cephalosporin APIs’ manufacturing facility in Dera Bassi, Punjab. The regulatory authority concluded that the facility, systems and practices comply with ANVISA cGMP requirements.
The facility is already approved by various international regulatory agencies such as US-FDA, MCC - South Africa, PMDA-Japan, OGYI-Hungary and KFDA- South Korea.
Brazil market for Cephalosporin’s is currently valued at $300 million between injectable and oral molecules. The company has highest capacities globally of all the approved molecules in Cephalosporin. This approval opens up very valuable market for NecLife for API’s as well as formulations for which Unit-6 located in Baddi is already approved by the ANVISA authority.
Nectar Lifesciences is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |